Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma.

Author: BauerS, ChiP, JankuF, JenningsJ, JonesR L, MeadeJ, PsoinosC, Ruiz-SotoR, ShoumariyehK, SpreaficoA

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigates the efficacy and safety of ripretinib, a broad-spectrum KIT and platelet-derived growth factor receptor A inhibitor, in patients with KIT-altered metastatic melanoma enrolled in the expansion phase of a phase I trial.
Paper Details　
Original Abstract of the Article :
Ripretinib, a broad-spectrum KIT and platelet-derived growth factor receptor A switch-control tyrosine kinase inhibitor, is approved for the treatment of adult patients with advanced gastrointestinal stromal tumor as ≥ fourth-line therapy. We present the efficacy and safety of ripretinib in patients...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434165/

データ提供：米国国立医学図書館（NLM）

Ripretinib for KIT-Altered Metastatic Melanoma

This study explores the efficacy and safety of ripretinib, a tyrosine kinase inhibitor, in patients with KIT-altered metastatic melanoma. Ripretinib has been approved for the treatment of gastrointestinal stromal tumors, and the researchers are investigating its potential efficacy in a different type of cancer, melanoma.

Ripretinib: A Potential New Treatment for Melanoma

The study provides insights into the efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma. The findings may contribute to the development of new treatment options for melanoma patients who have limited treatment choices. The researchers are investigating the potential of ripretinib as a targeted therapy for this type of cancer.

Navigating the Desert of Cancer

As a camel, I've witnessed the resilience of life in the desert, where even in the face of adversity, growth and renewal are possible. Cancer can feel like an endless desert, overwhelming and isolating. This study offers hope, demonstrating the potential of ripretinib to improve the treatment outcomes for patients with KIT-altered metastatic melanoma.

Dr.Camel's Conclusion

This research investigates the efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma, providing valuable insights into the potential of this tyrosine kinase inhibitor as a new treatment option for this type of cancer. The study highlights the importance of exploring novel therapies and personalized approaches to treating melanoma patients. Further research is needed to fully understand the long-term efficacy and safety of ripretinib in this patient population.

Date :
  1. Date Completed 2022-08-30
  2. Date Revised 2023-01-31
Further Info :

Pubmed ID

35753087

DOI: Digital Object Identifier

PMC9434165

Related Literature

Article Analysis
・Effects of ripretinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.